Keyphrases
Inclisiran
100%
Acute Myocardial Infarction
89%
Orion
76%
Acute Coronary Syndrome
63%
Low-density Lipoprotein Cholesterol (LDL-C)
59%
Convalescent Plasma
57%
Placebo
55%
Statin Therapy
46%
COVID-19
43%
ST-elevation Myocardial Infarction (STEMI)
42%
Statins
41%
Myocardial Infarction
40%
Confidence Interval
30%
Low-density Lipoprotein Cholesterol Level
27%
Coronary Artery Disease
26%
Chest Pain
26%
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
24%
Randomized Clinical Trial
24%
LDL Cholesterol
24%
Hazard Ratio
23%
Community-based Population
21%
Pooled Analysis
20%
COVID-19 Convalescent Plasma
19%
Hospitalization
19%
Long-term Survival
19%
Cardiac Intensive Care Unit
18%
Percutaneous Coronary Intervention
18%
Atherosclerotic Cardiovascular Disease (ASCVD)
18%
Mayo Clinic
17%
Small Interfering RNA (siRNA)
17%
Long-term Mortality
16%
Coronary Artery Bypass Grafting
16%
In-hospital Mortality
16%
Cardiac Arrest
16%
Left Ventricular Function
15%
Cardiovascular Events
15%
Revascularization
14%
Clinical Trials
14%
Mortality Prediction
14%
Myocardial Injury
14%
Mortality Risk
14%
Transient Left Ventricular Apical Ballooning Syndrome
14%
Primary Percutaneous Coronary Intervention
14%
Randomized Phase III Trial
14%
Convalescent Plasma Therapy
13%
Body Mass Index
13%
Alirocumab
13%
Lipid-lowering Therapy
12%
Obesity
12%
ST-segment Elevation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Inclisiran
100%
Low Density Lipoprotein Cholesterol
89%
Placebo
64%
Acute Heart Infarction
60%
Heart Infarction
56%
Statin (Protein)
53%
Acute Coronary Syndrome
51%
Coronary Artery Disease
28%
Randomized Clinical Trial
26%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
26%
Diseases
25%
Coronary Artery Atherosclerosis
24%
Adverse Event
23%
Proprotein Convertase 9
22%
Convalescence
20%
Small Interfering RNA
20%
ST Segment Elevation Myocardial Infarction
18%
Infarction
18%
Congestive Heart Failure
17%
Coronavirinae
16%
Cardiovascular Risk
15%
Cardiovascular Disease
15%
Clinical Trial
14%
High Density Lipoprotein Cholesterol
14%
Takotsubo Cardiomyopathy
14%
Hospital Mortality
13%
Long Term Survival
13%
Non ST Segment Elevation Myocardial Infarction
12%
Unstable Angina Pectoris
12%
Randomized Controlled Trial
11%
Alirocumab
11%
Lipoprotein A
11%
Prevalence
11%
Familial Hypercholesterolemia
11%
Dyslipidemia
11%
Dalcetrapib
11%
Hypercholesterolemia
10%
Cardiogenic Shock
10%
Thorax Pain
10%
Lipoprotein
10%
Syndrome
10%
Heart Muscle Injury
10%
Atherosclerosis
9%
Sleep Disordered Breathing
9%
Endothelin
9%
Inclacumab
9%
P-Selectin
9%
Selectin Antagonist
9%
Mortality Rate
9%
Tolerability
8%
Medicine and Dentistry
Inclisiran
61%
Low Density Lipoprotein Cholesterol
48%
Acute Heart Infarction
46%
Acute Coronary Syndrome
41%
Coronary Artery Disease
37%
Myocardial Infarction
35%
COVID-19
34%
Placebo
34%
Thorax Pain
29%
Diabetes
26%
Cardiovascular System
26%
Diseases
25%
ST Segment Elevation Myocardial Infarction
23%
Takotsubo Cardiomyopathy
23%
ST Elevation
22%
Coronary Care Unit
17%
Statin
16%
Long Term Survival
16%
Revascularization
16%
Electrocardiogram
15%
Coronary Artery Bypass Graft
15%
Heart Arrest
14%
Pooled Analysis
14%
Clinical Trial
14%
Adverse Event
14%
Hazard Ratio
14%
Infarction
13%
Cardiovascular Risk
12%
Hospital Mortality
12%
Congestive Heart Failure
11%
Convalescence
11%
Proprotein Convertase 9
10%
Randomized Clinical Trial
9%
Mitral Valve
9%
Angioplasty
9%
Blood Clot Lysis
9%
Primary Percutaneous Coronary Intervention
9%
Hypercholesterolemia
9%
Dalcetrapib
9%
Atherosclerosis
9%
Hip Fracture
9%
Familial Hypercholesterolemia
9%
Intensive Care
8%
Prevalence
8%
Small Interfering RNA
8%
Percutaneous Coronary Intervention
8%
Emergency Department
8%
APACHE II
8%
Odds Ratio
7%
Biological Marker
7%